DK2928865T3 - Biokatalytisk transamineringsfremgangsmåde - Google Patents

Biokatalytisk transamineringsfremgangsmåde Download PDF

Info

Publication number
DK2928865T3
DK2928865T3 DK13860923.5T DK13860923T DK2928865T3 DK 2928865 T3 DK2928865 T3 DK 2928865T3 DK 13860923 T DK13860923 T DK 13860923T DK 2928865 T3 DK2928865 T3 DK 2928865T3
Authority
DK
Denmark
Prior art keywords
val
leu
ala
asp
gly
Prior art date
Application number
DK13860923.5T
Other languages
English (en)
Inventor
Paul Gerard Bulger
Birgit Kosjek
Nelo Rivera
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK2928865T3 publication Critical patent/DK2928865T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • C12P17/12Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/02Preparation by ring-closure or hydrogenation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1096Transferases (2.) transferring nitrogenous groups (2.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/001Amines; Imines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y206/00Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01Transaminases (2.6.1)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (15)

  1. BIOKATALYTISK TRANSAMINERINGSFREMGANGSMÅDE
    1. Fremgangsmåde til fremstilling af en asymmetrisk forbindelse med formlen I:
    hvor: R1 er en fraspaltelig gruppe, en beskyttet aminogruppe, N02, eller OH eller dens beskyttede form; R2 er hydrogen; R3 er (C=0)0R5, CH2R6 eller et beskyttet aldehyd; eller R2 og R3 kombineres for at danne et nitrogenholdigt heterocyclyl, der er udvalgt fra
    R4 er hydrogen eller en aminobeskyttelsesgruppe; R5 er Ci_6 alkyl, C3.10-cycloalkyl, C4.i0-heterocyclyl, aryl eller heteroaryl; og R6 er en fraspaltelig gruppe eller OH eller dens beskyttede form; der omfatter en biokatalytisk transaminering af en forbindelse med formlen Π:
    hvor: R1 er som defineret ovenfor; R2 er et aldehyd eller en aldehydækvivalent; og R3 er R3; eller R2 og R3 kombineres for at danne
    i nærvær af et transaminasepolypeptid, et coenzym og en aminodonor.
  2. 2. Fremgangsmåde ifølge krav 1, hvor transaminasepolypeptidet er udvalgt fra SEQ ID NO: 18 eller SEQIDNO: 180.
  3. 3. Fremgangsmåde ifølge krav 2, hvor transaminasepolypeptidet er SEQ ID NO: 180.
  4. 4. Fremgangsmåde ifølge krav 1, hvor coenzymet er pyridoxal-phosphat (PLP).
  5. 5. Fremgangsmåde ifølge krav 1, hvor aminodonoren er isopropylamin.
  6. 6. Fremgangsmåde ifølge krav 1, hvor transaminasepolypeptidet er SEQ ID NO: 180, coenzymet er PLP og aminodonoren er isopropylamin.
  7. 7. Fremgangsmåde ifølge krav 1, hvor R1 er Br.
  8. 8. Fremgangsmåde ifølge krav 1, hvor R2 og R3 kombineres for at danne et nitrogenholdigt heterocyclyl udvalgt fra
    og R4 er hydrogen.
  9. 9. Fremgangsmåde ifølge krav 8, hvor R2 og R3 kombineres for at danne
    og R4 er hydrogen.
  10. 10. Fremgangsmåde ifølge krav 1, hvor R1 er Br, R2 og R3 kombineres for at danne
    og R4 er hydrogen.
  11. 11. Fremgangsmåde ifølge krav 1, hvor R2 er hydrogen, R3 er CH2R5, R4 er hydrogen og R5 er OH.
  12. 12. Fremgangsmåde til fremstilling af en asymmetrisk forbindelse med formlen III:
    der omfatter en biokatalytisk transaminering af en forbindelse med formlen IV eller en forbindelse med formlen V:
    i nærvær af et transaminasepolypeptid, et coenzym og en aminodonor.
  13. 13. Fremgangsmåde ifølge krav 12, hvor transaminasepolypeptidet er udvalgt fra SEQ ID NO: 18 eller SEQIDNO: 180.
  14. 14. Fremgangsmåde ifølge krav 13, hvor transaminasepolypeptidet er SEQ ID NO: 180, coenzymet er PLP og aminodonoren er isopropylamin.
  15. 15. Fremgangsmåde til fremstilling af en asymmetrisk forbindelse med formlen VI:
    der omfatter: (a) en biokatalytisk transaminering af en forbindelse med formlen IV eller en forbindelse med formlen V:
    i nærvær af et transaminasepolypeptid, et coenzym og en aminodonor, hvorved forbindelsen med formlen III dannes:
    (b) reduktion af lactam i forbindelsen med formlen ΠΙ, hvorved forbindelsen med formlen VII dannes:
    VTT ; Og (c) beskyttelse af piperidinnitrogenet i forbindelsen med formlen VII for at danne forbindelsen med formlen VI.
DK13860923.5T 2012-12-07 2013-12-03 Biokatalytisk transamineringsfremgangsmåde DK2928865T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261734394P 2012-12-07 2012-12-07
PCT/US2013/072711 WO2014088984A1 (en) 2012-12-07 2013-12-03 Biocatalytic transamination process

Publications (1)

Publication Number Publication Date
DK2928865T3 true DK2928865T3 (da) 2018-06-18

Family

ID=50883910

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13860923.5T DK2928865T3 (da) 2012-12-07 2013-12-03 Biokatalytisk transamineringsfremgangsmåde

Country Status (7)

Country Link
US (2) US9738915B2 (da)
EP (2) EP2928865B1 (da)
DK (1) DK2928865T3 (da)
ES (1) ES2672328T3 (da)
NO (1) NO3021971T3 (da)
PT (1) PT2928865T (da)
WO (1) WO2014088984A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
HUE062956T2 (hu) 2017-08-14 2023-12-28 Teva Pharmaceuticals Int Gmbh Eljárások niraparib és köztitermékei elõállítására
CN107311911B (zh) * 2017-08-21 2020-09-08 钟桂发 一种尼拉帕尼的手性中间体的制备方法
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼(niraparib)調配物
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
CN107759506B (zh) * 2017-12-02 2021-04-23 四川同晟生物医药有限公司 一种尼拉帕布中间体s-3-(4-溴苯基)哌啶的制备方法
CN111918667A (zh) 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
CN110698388A (zh) * 2019-11-01 2020-01-17 暨明医药科技(苏州)有限公司 一种工业化生产(s)-3-(4-溴苯基)哌啶的方法
CN111592467B (zh) * 2020-05-20 2022-12-13 宁波人健化学制药有限公司 尼拉帕尼中间体及其制备方法和用途和尼拉帕尼的合成方法
WO2022251402A1 (en) * 2021-05-28 2022-12-01 Merck Sharp & Dohme Llc Transaminase enzymes for the transamination of (1s,5r)-6,8-dioxabicyclo[3.2.1]octan-4-one
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
CN114507651A (zh) * 2022-03-03 2022-05-17 西南交通大学 一种重组转氨酶及其在制备尼拉帕利手性中间体中的应用
CN119698468A (zh) * 2022-08-26 2025-03-25 特沙诺有限公司 生物催化剂及其方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
WO1998048030A1 (en) 1997-04-23 1998-10-29 Kaneka Corporation Process for producing optically active amino compounds
US6537746B2 (en) 1997-12-08 2003-03-25 Maxygen, Inc. Method for creating polynucleotide and polypeptide sequences
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1272967A2 (en) 2000-03-30 2003-01-08 Maxygen, Inc. In silico cross-over site selection
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
EP2132322A4 (en) 2007-03-02 2013-02-20 Richmond Chemical Corp METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE
US20100222326A1 (en) 2007-04-27 2010-09-02 Ucb Pharma, S.A. New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders
JP5707344B2 (ja) 2009-02-26 2015-04-30 コデクシス, インコーポレイテッド トランスアミナーゼ生体触媒
JP2010269667A (ja) 2009-05-20 2010-12-02 Alps Electric Co Ltd 多回転角度検出装置
EP2606139B1 (en) 2010-08-16 2015-07-15 Codexis, Inc. Biocatalysts and methods for the synthesis of (1r,2r)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives

Also Published As

Publication number Publication date
NO3021971T3 (da) 2018-02-10
PT2928865T (pt) 2018-06-11
WO2014088984A1 (en) 2014-06-12
US9738915B2 (en) 2017-08-22
US20170335359A1 (en) 2017-11-23
EP3406594A1 (en) 2018-11-28
US20160040201A1 (en) 2016-02-11
EP2928865A4 (en) 2016-08-24
EP2928865A1 (en) 2015-10-14
ES2672328T3 (es) 2018-06-13
US10407702B2 (en) 2019-09-10
EP2928865B1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
DK2928865T3 (da) Biokatalytisk transamineringsfremgangsmåde
US12371678B2 (en) Engineered transaminase polypeptides for industrial biocatalysis
US12163162B2 (en) Biocatalysts and methods for the synthesis of substituted lactams
EP2828385B1 (en) Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
EP2606139B1 (en) Biocatalysts and methods for the synthesis of (1r,2r)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
EP2935572B1 (en) Engineered biocatalysts and methods for synthesizing chiral amines
IL296841A (en) Transaminase transaminase polypeptides